Incretin-based medications for type 2 diabetes: an overview of reviews

Diabetes, Obesity & Metabolism
J-M GambleE M Davis

Abstract

To summarize evidence from and assess the quality of published systematic reviews evaluating the safety, efficacy and effectiveness of incretin-based medications used in the treatment of type 2 diabetes. We identified systematic reviews of randomized controlled trials or observational studies published in any language that evaluated the safety and/or effectiveness of glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl-peptidase-4 (DPP-4) inhibitors. Data sources used include the Cochrane Library, PubMed, EMBASE, Web of Science, International Pharmaceutical Abstracts, table of contents of diabetes journals, and hand-searching of reference lists and clinical practice guidelines. The methodological quality of systematic reviews was independently assessed by two reviewers using the Assessment of Multiple Systematic Reviews (AMSTAR) checklist. Our study protocol was registered with PROSPERO (2013:CRD42013005149). The primary outcomes were pooled treatment effect estimates for glycaemic control, macrovascular and microvascular complications, and hypoglycaemic events. We identified 467 unique citations of which 84 systematic reviews met our inclusion criteria. There were 51 reviews that evaluated GLP-1 receptor agonists an...Continue Reading

References

Jun 19, 2004·BMJ : British Medical Journal·David AtkinsUNKNOWN GRADE Working Group
Mar 29, 2007·PLoS Medicine·David MoherDouglas G Altman
Jan 30, 2008·Circulation·Silvio E Inzucchi, Darren K McGuire
Jun 4, 2008·Annals of Internal Medicine·Susan L NorrisUNKNOWN U.S. Preventive Services Task Force
Feb 24, 2009·Journal of Clinical Epidemiology·Beverley J SheaMaarten Boers
Mar 25, 2010·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·L MonastaJ Brug
Feb 5, 2011·BMC Medical Research Methodology·Valerie SmithMike Clarke
Mar 23, 2011·Journal of the American Medical Informatics Association : JAMIA·Monique W M JaspersLinda W Peute
May 6, 2011·Diabetes Care·Simona Cernea, Itamar Raz
May 18, 2011·Annals of Internal Medicine·Jorge L GrossUNKNOWN Diabetes and Endocrinology Meta-analysis Group (DEMA)
Mar 20, 2012·The American Journal of Cardiology·Steven G Chrysant, George S Chrysant
Aug 30, 2012·BMC Medical Research Methodology·Hyun-Ju Seo, Kyeong Uoon Kim
Jul 23, 2013·BMJ : British Medical Journal·Konstantinos C SiontisJohn P A Ioannidis
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Jan 18, 2017·Diabetes, Obesity & Metabolism·Manfredi RizzoGiorgio Sesti
Apr 6, 2017·The Journal of Clinical Endocrinology and Metabolism·Tuuli SedmanVallo Volke
Oct 6, 2015·Endocrinology and Metabolism·Eun Jung Rhee
Apr 16, 2016·Molecular Endocrinology·Oleg G ChepurnyColin A Leech
Mar 14, 2019·Scientific Reports·Romain GirardFrançois Boudreau
Jan 25, 2018·Diabetes, Obesity & Metabolism·Sudesna ChatterjeeKamlesh Khunti
Dec 10, 2020·Sensors·Liu TangJen-Tsai Liu
Jun 12, 2021·Environmental Research·Fábio Hech DominskiAlexandro Andrade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.